Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA203/IMA203CD8 With or Without Nivolumab in Recurrent/Refractory Solid Tumors
NCT03686124Phase 2Recruiting
- Sponsor
- Immatics
- Start
- May 2019
- Primary completion
- Dec 2028
- Modality
- TCR-Engineered T Cells
- Countries
- 2
01
Overview
Phase 2, open-label trial of PRAME TCR T cells and IMA203CD8 in solid tumor, Uveal melanoma (UM), ovarian cancer and 4 more (12 arms), sponsored by Immatics. Primary endpoints: Maximum Tolerated Dose and/or Recommended Dose for Extension at 28 days, Treatment Emergent Adverse Events and Adverse Events of Special Interest at 35 days and 1 more. Started May 2019; status: recruiting.
02
Drugs
PRAME TCR T cellsIMA203CD8
03
Conditions
solid tumorUveal melanoma (UM)ovarian cancerendometrial cancer (EC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT03686124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03686124.